Stem definition | Drug id | CAS RN |
---|---|---|
dipeptidyl aminopeptidase-IV inhibitors | 4175 | 668270-12-0 |
Dose | Unit | Route |
---|---|---|
5 | mg | O |
Property | Value | Reference |
---|---|---|
Vd (Volume of distribution) | 16 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 1.90 mL/min/kg | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 129 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
May 2, 2011 | FDA | BOEHRINGER INGELHEIM | |
July 1, 2011 | PMDA | Nippon Boehringer Ingelheim Co., Ltd |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Hypoglycaemia | 211.78 | 15.23 | 141 | 12665 | 55674 | 56223587 |
Pemphigoid | 207.72 | 15.23 | 71 | 12735 | 6229 | 56273032 |
Pancreatitis | 164.03 | 15.23 | 111 | 12695 | 44969 | 56234292 |
Blood glucose increased | 151.32 | 15.23 | 130 | 12676 | 75021 | 56204240 |
Acute kidney injury | 112.03 | 15.23 | 198 | 12608 | 240565 | 56038696 |
Glycosylated haemoglobin increased | 95.70 | 15.23 | 48 | 12758 | 11117 | 56268144 |
Dermatitis bullous | 93.92 | 15.23 | 42 | 12764 | 7531 | 56271730 |
Renal impairment | 91.54 | 15.23 | 102 | 12704 | 80611 | 56198650 |
Hyperglycaemia | 82.67 | 15.23 | 69 | 12737 | 38212 | 56241049 |
Hyperlactacidaemia | 65.60 | 15.23 | 24 | 12782 | 2564 | 56276697 |
Subarachnoid haemorrhage | 64.14 | 15.23 | 37 | 12769 | 11310 | 56267951 |
Diabetes mellitus inadequate control | 59.49 | 15.23 | 38 | 12768 | 13942 | 56265319 |
Diabetic ketoacidosis | 58.14 | 15.23 | 42 | 12764 | 18829 | 56260432 |
Rheumatoid arthritis | 57.86 | 15.23 | 9 | 12797 | 382595 | 55896666 |
Euglycaemic diabetic ketoacidosis | 57.24 | 15.23 | 23 | 12783 | 3166 | 56276095 |
Hyperkalaemia | 57.14 | 15.23 | 64 | 12742 | 50801 | 56228460 |
Metabolic acidosis | 56.23 | 15.23 | 57 | 12749 | 40397 | 56238864 |
Pancreatic carcinoma | 55.85 | 15.23 | 29 | 12777 | 7212 | 56272049 |
Cardiac failure | 53.76 | 15.23 | 79 | 12727 | 82014 | 56197247 |
Chronic kidney disease | 52.60 | 15.23 | 56 | 12750 | 42000 | 56237261 |
Blood glucose abnormal | 50.23 | 15.23 | 27 | 12779 | 7201 | 56272060 |
Pancreatitis acute | 49.55 | 15.23 | 43 | 12763 | 25081 | 56254180 |
Cystostomy | 48.86 | 15.23 | 9 | 12797 | 55 | 56279206 |
Pain | 47.17 | 15.23 | 49 | 12757 | 663135 | 55616126 |
Lactic acidosis | 44.08 | 15.23 | 47 | 12759 | 35299 | 56243962 |
Glomerular filtration rate decreased | 43.93 | 15.23 | 30 | 12776 | 12299 | 56266962 |
Diabetic metabolic decompensation | 41.64 | 15.23 | 15 | 12791 | 1533 | 56277728 |
Renal failure | 40.22 | 15.23 | 82 | 12724 | 110418 | 56168843 |
Drug ineffective | 39.65 | 15.23 | 95 | 12711 | 918894 | 55360367 |
Dizziness | 36.09 | 15.23 | 175 | 12631 | 375965 | 55903296 |
Diabetes mellitus | 33.42 | 15.23 | 50 | 12756 | 52685 | 56226576 |
Blood glucose decreased | 32.35 | 15.23 | 30 | 12776 | 19057 | 56260204 |
Systemic lupus erythematosus | 30.18 | 15.23 | 3 | 12803 | 180075 | 56099186 |
Urinary tract infection | 29.92 | 15.23 | 121 | 12685 | 240392 | 56038869 |
Rhabdomyolysis | 29.34 | 15.23 | 41 | 12765 | 40617 | 56238644 |
Lethargy | 28.72 | 15.23 | 46 | 12760 | 51395 | 56227866 |
Ketoacidosis | 27.69 | 15.23 | 15 | 12791 | 4060 | 56275201 |
Shock | 27.28 | 15.23 | 29 | 12777 | 21699 | 56257562 |
Contraindicated product administered | 26.75 | 15.23 | 5 | 12801 | 186281 | 56092980 |
Urine calcium/creatinine ratio increased | 26.39 | 15.23 | 6 | 12800 | 114 | 56279147 |
Blood creatinine increased | 26.24 | 15.23 | 57 | 12749 | 80134 | 56199127 |
Altered state of consciousness | 25.89 | 15.23 | 29 | 12777 | 22992 | 56256269 |
Hypoglycaemic encephalopathy | 25.72 | 15.23 | 7 | 12799 | 283 | 56278978 |
Mucosal membrane hyperplasia | 25.65 | 15.23 | 5 | 12801 | 43 | 56279218 |
Arthropathy | 25.51 | 15.23 | 7 | 12799 | 200268 | 56078993 |
Decreased appetite | 24.68 | 15.23 | 107 | 12699 | 219124 | 56060137 |
Drug intolerance | 24.47 | 15.23 | 15 | 12791 | 264803 | 56014458 |
Hypomagnesaemia | 23.94 | 15.23 | 29 | 12777 | 24986 | 56254275 |
Insulin-like growth factor decreased | 23.63 | 15.23 | 7 | 12799 | 385 | 56278876 |
Therapeutic product effect decreased | 23.38 | 15.23 | 5 | 12801 | 169447 | 56109814 |
Albuminuria | 23.37 | 15.23 | 6 | 12800 | 193 | 56279068 |
Bite | 23.14 | 15.23 | 7 | 12799 | 414 | 56278847 |
Pemphigus | 23.04 | 15.23 | 4 | 12802 | 157208 | 56122053 |
Pyelonephritis | 23.03 | 15.23 | 23 | 12783 | 16001 | 56263260 |
Urethral caruncle | 22.57 | 15.23 | 5 | 12801 | 84 | 56279177 |
Wound | 21.55 | 15.23 | 3 | 12803 | 138801 | 56140460 |
Infusion related reaction | 20.48 | 15.23 | 11 | 12795 | 208920 | 56070341 |
Parathyroid hyperplasia | 20.04 | 15.23 | 5 | 12801 | 143 | 56279118 |
Lipase increased | 18.98 | 15.23 | 16 | 12790 | 8963 | 56270298 |
Glossodynia | 18.19 | 15.23 | 6 | 12800 | 152452 | 56126809 |
Blood potassium increased | 18.15 | 15.23 | 21 | 12785 | 17240 | 56262021 |
Discomfort | 17.96 | 15.23 | 5 | 12801 | 141756 | 56137505 |
Post procedural infection | 17.93 | 15.23 | 15 | 12791 | 8317 | 56270944 |
Mesenteric vein thrombosis | 17.24 | 15.23 | 7 | 12799 | 990 | 56278271 |
Tubulointerstitial nephritis | 17.06 | 15.23 | 20 | 12786 | 16645 | 56262616 |
Vomiting | 16.31 | 15.23 | 179 | 12627 | 498049 | 55781212 |
Pancreatic enzymes increased | 16.05 | 15.23 | 6 | 12800 | 681 | 56278580 |
Food refusal | 15.84 | 15.23 | 5 | 12801 | 341 | 56278920 |
Drug hypersensitivity | 15.65 | 15.23 | 24 | 12782 | 275181 | 56004080 |
Toxic encephalopathy | 15.57 | 15.23 | 12 | 12794 | 5926 | 56273335 |
Alopecia | 15.38 | 15.23 | 27 | 12779 | 293431 | 55985830 |
Staphylococcal sepsis | 15.34 | 15.23 | 13 | 12793 | 7336 | 56271925 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Pemphigoid | 492.35 | 14.43 | 178 | 16076 | 8093 | 31672997 |
Pancreatitis | 177.79 | 14.43 | 147 | 16107 | 35624 | 31645466 |
Hypoglycaemia | 165.83 | 14.43 | 165 | 16089 | 50781 | 31630309 |
Dermatitis bullous | 152.36 | 14.43 | 71 | 16183 | 6174 | 31674916 |
Glycosylated haemoglobin increased | 128.75 | 14.43 | 75 | 16179 | 10325 | 31670765 |
Blood glucose increased | 124.65 | 14.43 | 155 | 16099 | 60928 | 31620162 |
Blood mercury abnormal | 78.36 | 14.43 | 19 | 16235 | 203 | 31680887 |
5-hydroxyindolacetic acid in urine increased | 76.49 | 14.43 | 19 | 16235 | 226 | 31680864 |
Cardiac failure | 73.26 | 14.43 | 146 | 16108 | 85807 | 31595283 |
Left ventricular dysfunction | 67.40 | 14.43 | 48 | 16206 | 9309 | 31671781 |
Pericardial disease | 66.98 | 14.43 | 19 | 16235 | 387 | 31680703 |
Pulmonary valve disease | 61.96 | 14.43 | 17 | 16237 | 305 | 31680785 |
Euglycaemic diabetic ketoacidosis | 55.94 | 14.43 | 28 | 16226 | 2846 | 31678244 |
Diastolic dysfunction | 51.94 | 14.43 | 33 | 16221 | 5302 | 31675788 |
Diabetic ketoacidosis | 51.69 | 14.43 | 53 | 16201 | 16852 | 31664238 |
Cerebral infarction | 49.85 | 14.43 | 64 | 16190 | 25913 | 31655177 |
Low density lipoprotein decreased | 49.08 | 14.43 | 19 | 16235 | 1041 | 31680049 |
Acute kidney injury | 46.66 | 14.43 | 273 | 15981 | 279441 | 31401649 |
Physical examination abnormal | 44.88 | 14.43 | 13 | 16241 | 286 | 31680804 |
Ventricular hyperkinesia | 44.39 | 14.43 | 12 | 16242 | 203 | 31680887 |
Hyperglycaemia | 43.84 | 14.43 | 72 | 16182 | 36404 | 31644686 |
Stenosis | 43.32 | 14.43 | 18 | 16236 | 1187 | 31679903 |
Right atrial enlargement | 43.14 | 14.43 | 12 | 16242 | 227 | 31680863 |
Renal impairment | 43.10 | 14.43 | 119 | 16135 | 86230 | 31594860 |
Mean platelet volume increased | 41.91 | 14.43 | 14 | 16240 | 499 | 31680591 |
Rales | 41.80 | 14.43 | 35 | 16219 | 8604 | 31672486 |
Hepatic neoplasm | 41.27 | 14.43 | 20 | 16234 | 1895 | 31679195 |
Diabetic nephropathy | 40.25 | 14.43 | 20 | 16234 | 2001 | 31679089 |
Hypochromasia | 40.09 | 14.43 | 12 | 16242 | 297 | 31680793 |
Pancreatitis acute | 38.42 | 14.43 | 56 | 16198 | 25544 | 31655546 |
Pancreatic carcinoma | 37.85 | 14.43 | 33 | 16221 | 8567 | 31672523 |
Mitral valve thickening | 37.52 | 14.43 | 12 | 16242 | 372 | 31680718 |
Tricuspid valve incompetence | 37.10 | 14.43 | 33 | 16221 | 8796 | 31672294 |
Cardiac discomfort | 36.97 | 14.43 | 13 | 16241 | 542 | 31680548 |
Blood glucose abnormal | 35.18 | 14.43 | 26 | 16228 | 5337 | 31675753 |
Diabetes mellitus | 34.66 | 14.43 | 71 | 16183 | 42485 | 31638605 |
Drug abuse | 33.93 | 14.43 | 3 | 16251 | 87755 | 31593335 |
Chronic kidney disease | 32.89 | 14.43 | 65 | 16189 | 37910 | 31643180 |
Left ventricular enlargement | 30.81 | 14.43 | 12 | 16242 | 668 | 31680422 |
Mitral valve incompetence | 30.81 | 14.43 | 37 | 16217 | 13996 | 31667094 |
Mucosal dryness | 30.65 | 14.43 | 14 | 16240 | 1161 | 31679929 |
Echocardiogram abnormal | 30.45 | 14.43 | 13 | 16241 | 917 | 31680173 |
Hyperkalaemia | 30.43 | 14.43 | 87 | 16167 | 64264 | 31616826 |
Bundle branch block left | 30.15 | 14.43 | 24 | 16230 | 5494 | 31675596 |
Aortic valve incompetence | 30.07 | 14.43 | 24 | 16230 | 5517 | 31675573 |
Necrotising oesophagitis | 30.02 | 14.43 | 11 | 16243 | 517 | 31680573 |
Expired product administered | 29.96 | 14.43 | 19 | 16235 | 3042 | 31678048 |
Haematocrit increased | 29.78 | 14.43 | 16 | 16238 | 1881 | 31679209 |
Mitral valve disease | 29.68 | 14.43 | 14 | 16240 | 1249 | 31679841 |
Neoplasm | 29.55 | 14.43 | 22 | 16232 | 4564 | 31676526 |
Hepatojugular reflux | 29.32 | 14.43 | 11 | 16243 | 553 | 31680537 |
Electrocardiogram Q wave abnormal | 29.15 | 14.43 | 10 | 16244 | 387 | 31680703 |
Left atrial enlargement | 29.15 | 14.43 | 12 | 16242 | 773 | 31680317 |
Pericardial haemorrhage | 27.73 | 14.43 | 18 | 16236 | 2999 | 31678091 |
Occult blood | 27.72 | 14.43 | 11 | 16243 | 644 | 31680446 |
Hypoglycaemic coma | 27.43 | 14.43 | 16 | 16238 | 2205 | 31678885 |
Completed suicide | 26.66 | 14.43 | 7 | 16247 | 91507 | 31589583 |
Hypohidrosis | 26.35 | 14.43 | 8 | 16246 | 208 | 31680882 |
Ventricular arrhythmia | 26.14 | 14.43 | 21 | 16233 | 4870 | 31676220 |
Acute lung injury | 25.85 | 14.43 | 13 | 16241 | 1334 | 31679756 |
Bronchitis viral | 25.42 | 14.43 | 8 | 16246 | 235 | 31680855 |
Peak expiratory flow rate decreased | 25.39 | 14.43 | 7 | 16247 | 128 | 31680962 |
Left atrial dilatation | 25.33 | 14.43 | 14 | 16240 | 1741 | 31679349 |
Interstitial lung disease | 25.23 | 14.43 | 79 | 16175 | 61324 | 31619766 |
Dyspnoea at rest | 25.16 | 14.43 | 18 | 16236 | 3513 | 31677577 |
Hypovolaemia | 25.14 | 14.43 | 26 | 16228 | 8346 | 31672744 |
Haemoglobin increased | 24.75 | 14.43 | 17 | 16237 | 3109 | 31677981 |
Helicobacter gastritis | 24.17 | 14.43 | 12 | 16242 | 1198 | 31679892 |
Diabetes mellitus inadequate control | 23.82 | 14.43 | 31 | 16223 | 12710 | 31668380 |
Poikilocytosis | 23.51 | 14.43 | 7 | 16247 | 170 | 31680920 |
Blood iron decreased | 22.69 | 14.43 | 19 | 16235 | 4671 | 31676419 |
Eosinophilic pneumonia | 22.56 | 14.43 | 16 | 16238 | 3081 | 31678009 |
Left ventricular hypertrophy | 22.43 | 14.43 | 23 | 16231 | 7309 | 31673781 |
Amylase increased | 22.13 | 14.43 | 20 | 16234 | 5442 | 31675648 |
Off label use | 21.75 | 14.43 | 98 | 16156 | 347176 | 31333914 |
Drug ineffective | 21.69 | 14.43 | 117 | 16137 | 395456 | 31285634 |
Rhinalgia | 21.54 | 14.43 | 8 | 16246 | 391 | 31680699 |
Lactic acidosis | 21.11 | 14.43 | 49 | 16205 | 31888 | 31649202 |
Red blood cell count decreased | 20.97 | 14.43 | 44 | 16210 | 26763 | 31654327 |
Glomerular filtration rate decreased | 20.84 | 14.43 | 28 | 16226 | 11837 | 31669253 |
Carotid artery stenosis | 20.77 | 14.43 | 18 | 16236 | 4634 | 31676456 |
Supraventricular tachycardia | 20.72 | 14.43 | 26 | 16228 | 10281 | 31670809 |
Electrocardiogram T wave inversion | 20.69 | 14.43 | 13 | 16241 | 2047 | 31679043 |
Respiratory symptom | 20.46 | 14.43 | 11 | 16243 | 1295 | 31679795 |
Product use in unapproved indication | 20.17 | 14.43 | 13 | 16241 | 99158 | 31581932 |
Metabolic acidosis | 20.17 | 14.43 | 55 | 16199 | 39522 | 31641568 |
Hypertensive heart disease | 20.01 | 14.43 | 13 | 16241 | 2168 | 31678922 |
Diabetic ketoacidotic hyperglycaemic coma | 19.99 | 14.43 | 6 | 16248 | 150 | 31680940 |
Carotid arteriosclerosis | 19.98 | 14.43 | 12 | 16242 | 1745 | 31679345 |
Hyperaesthesia teeth | 19.74 | 14.43 | 8 | 16246 | 495 | 31680595 |
Syncope | 19.54 | 14.43 | 91 | 16163 | 85091 | 31595999 |
Bronchial hyperreactivity | 19.42 | 14.43 | 11 | 16243 | 1434 | 31679656 |
Lipase increased | 18.89 | 14.43 | 23 | 16231 | 8820 | 31672270 |
Dust allergy | 18.52 | 14.43 | 8 | 16246 | 581 | 31680509 |
Blindness transient | 18.45 | 14.43 | 12 | 16242 | 2005 | 31679085 |
Hepatic function abnormal | 17.82 | 14.43 | 54 | 16200 | 41168 | 31639922 |
Pain | 17.63 | 14.43 | 44 | 16210 | 186715 | 31494375 |
Hyperlactacidaemia | 17.29 | 14.43 | 13 | 16241 | 2737 | 31678353 |
Erythema multiforme | 17.25 | 14.43 | 21 | 16233 | 8050 | 31673040 |
Skin disorder | 17.18 | 14.43 | 26 | 16228 | 12255 | 31668835 |
Blood chloride increased | 17.12 | 14.43 | 13 | 16241 | 2778 | 31678312 |
Sputum discoloured | 16.76 | 14.43 | 19 | 16235 | 6757 | 31674333 |
Epidermolysis | 16.34 | 14.43 | 6 | 16248 | 284 | 31680806 |
Intestinal obstruction | 16.31 | 14.43 | 34 | 16220 | 20576 | 31660514 |
Haemodynamic instability | 16.24 | 14.43 | 21 | 16233 | 8554 | 31672536 |
Eosinophil count increased | 16.22 | 14.43 | 20 | 16234 | 7771 | 31673319 |
Marasmus | 16.12 | 14.43 | 7 | 16247 | 515 | 31680575 |
High density lipoprotein decreased | 15.73 | 14.43 | 13 | 16241 | 3137 | 31677953 |
Oral mucosal blistering | 15.25 | 14.43 | 10 | 16244 | 1695 | 31679395 |
Latent autoimmune diabetes in adults | 15.18 | 14.43 | 4 | 16250 | 61 | 31681029 |
Incontinence | 14.87 | 14.43 | 16 | 16238 | 5370 | 31675720 |
Renal failure | 14.76 | 14.43 | 111 | 16143 | 123219 | 31557871 |
Ventricular hypokinesia | 14.56 | 14.43 | 15 | 16239 | 4791 | 31676299 |
Anaemia macrocytic | 14.55 | 14.43 | 12 | 16242 | 2888 | 31678202 |
Haematocrit decreased | 14.54 | 14.43 | 41 | 16213 | 30020 | 31651070 |
Immune-mediated myositis | 14.49 | 14.43 | 10 | 16244 | 1842 | 31679248 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Pemphigoid | 675.67 | 12.74 | 238 | 26358 | 13784 | 70888064 |
Hypoglycaemia | 335.71 | 12.74 | 280 | 26316 | 94084 | 70807764 |
Pancreatitis | 224.87 | 12.74 | 187 | 26409 | 62481 | 70839367 |
Blood glucose increased | 188.21 | 12.74 | 212 | 26384 | 102770 | 70799078 |
Dermatitis bullous | 187.90 | 12.74 | 93 | 26503 | 12664 | 70889184 |
Glycosylated haemoglobin increased | 179.70 | 12.74 | 100 | 26496 | 17291 | 70884557 |
Acute kidney injury | 159.19 | 12.74 | 463 | 26133 | 474161 | 70427687 |
Cardiac failure | 132.92 | 12.74 | 212 | 26384 | 143329 | 70758519 |
Diabetic ketoacidosis | 114.97 | 12.74 | 95 | 26501 | 31417 | 70870431 |
Renal impairment | 111.12 | 12.74 | 196 | 26400 | 143741 | 70758107 |
Euglycaemic diabetic ketoacidosis | 110.41 | 12.74 | 51 | 26545 | 5956 | 70895892 |
Hyperglycaemia | 102.79 | 12.74 | 124 | 26472 | 64548 | 70837300 |
Chronic kidney disease | 92.06 | 12.74 | 114 | 26482 | 60943 | 70840905 |
Blood mercury abnormal | 84.27 | 12.74 | 19 | 26577 | 203 | 70901645 |
Pancreatic carcinoma | 83.58 | 12.74 | 55 | 26541 | 12849 | 70888999 |
5-hydroxyindolacetic acid in urine increased | 82.25 | 12.74 | 19 | 26577 | 228 | 70901620 |
Hyperkalaemia | 80.74 | 12.74 | 144 | 26452 | 106447 | 70795401 |
Diabetes mellitus inadequate control | 77.90 | 12.74 | 66 | 26530 | 22579 | 70879269 |
Pain | 71.97 | 12.74 | 78 | 26518 | 628738 | 70273110 |
Pulmonary valve disease | 69.17 | 12.74 | 17 | 26579 | 270 | 70901578 |
Hyperlactacidaemia | 68.86 | 12.74 | 35 | 26561 | 5037 | 70896811 |
Metabolic acidosis | 67.63 | 12.74 | 109 | 26487 | 74237 | 70827611 |
Pericardial disease | 67.39 | 12.74 | 19 | 26577 | 524 | 70901324 |
Drug ineffective | 66.76 | 12.74 | 160 | 26436 | 939592 | 69962256 |
Diabetes mellitus | 64.92 | 12.74 | 105 | 26491 | 71719 | 70830129 |
Rheumatoid arthritis | 62.82 | 12.74 | 16 | 26580 | 291789 | 70610059 |
Completed suicide | 60.79 | 12.74 | 7 | 26589 | 227128 | 70674720 |
Lactic acidosis | 58.68 | 12.74 | 95 | 26501 | 64929 | 70836919 |
Glomerular filtration rate decreased | 58.42 | 12.74 | 54 | 26542 | 20702 | 70881146 |
Pancreatitis acute | 58.06 | 12.74 | 78 | 26518 | 45146 | 70856702 |
Left ventricular dysfunction | 57.02 | 12.74 | 50 | 26546 | 17907 | 70883941 |
Cerebral infarction | 54.93 | 12.74 | 74 | 26522 | 42935 | 70858913 |
Low density lipoprotein decreased | 53.69 | 12.74 | 19 | 26577 | 1111 | 70900737 |
Renal failure | 51.53 | 12.74 | 172 | 26424 | 188898 | 70712950 |
Blood glucose abnormal | 50.66 | 12.74 | 36 | 26560 | 9521 | 70892327 |
Physical examination abnormal | 49.53 | 12.74 | 13 | 26583 | 272 | 70901576 |
Diastolic dysfunction | 46.50 | 12.74 | 34 | 26562 | 9399 | 70892449 |
Diabetic nephropathy | 46.19 | 12.74 | 22 | 26574 | 2751 | 70899097 |
Ventricular hyperkinesia | 45.27 | 12.74 | 12 | 26584 | 261 | 70901587 |
Right atrial enlargement | 42.81 | 12.74 | 12 | 26584 | 324 | 70901524 |
Drug abuse | 40.77 | 12.74 | 4 | 26592 | 147252 | 70754596 |
Mitral valve thickening | 40.39 | 12.74 | 12 | 26584 | 400 | 70901448 |
Interstitial lung disease | 39.64 | 12.74 | 107 | 26489 | 104578 | 70797270 |
Stenosis | 39.28 | 12.74 | 18 | 26578 | 2063 | 70899785 |
Subarachnoid haemorrhage | 38.75 | 12.74 | 42 | 26554 | 19462 | 70882386 |
Product use in unapproved indication | 38.18 | 12.74 | 15 | 26581 | 207463 | 70694385 |
Cystostomy | 37.78 | 12.74 | 8 | 26588 | 62 | 70901786 |
Hepatic neoplasm | 37.48 | 12.74 | 20 | 26576 | 3180 | 70898668 |
Therapeutic product effect decreased | 36.81 | 12.74 | 5 | 26591 | 143013 | 70758835 |
Mean platelet volume increased | 36.11 | 12.74 | 14 | 26582 | 1058 | 70900790 |
Altered state of consciousness | 35.45 | 12.74 | 58 | 26538 | 39964 | 70861884 |
Ketoacidosis | 35.38 | 12.74 | 26 | 26570 | 7243 | 70894605 |
Cardiac discomfort | 34.91 | 12.74 | 14 | 26582 | 1157 | 70900691 |
Treatment failure | 34.90 | 12.74 | 6 | 26590 | 144136 | 70757712 |
Hypochromasia | 34.58 | 12.74 | 12 | 26584 | 662 | 70901186 |
Synovitis | 34.52 | 12.74 | 4 | 26592 | 129224 | 70772624 |
Haemoglobin increased | 34.11 | 12.74 | 23 | 26573 | 5592 | 70896256 |
Left ventricular enlargement | 33.89 | 12.74 | 12 | 26584 | 703 | 70901145 |
Left ventricular hypertrophy | 33.58 | 12.74 | 29 | 26567 | 10173 | 70891675 |
Diabetic metabolic decompensation | 32.75 | 12.74 | 18 | 26578 | 3034 | 70898814 |
Arthropathy | 32.71 | 12.74 | 8 | 26588 | 150049 | 70751799 |
Blood iron decreased | 32.56 | 12.74 | 32 | 26564 | 13229 | 70888619 |
Rales | 32.48 | 12.74 | 36 | 26560 | 17099 | 70884749 |
Hepatojugular reflux | 31.80 | 12.74 | 11 | 26585 | 601 | 70901247 |
Hypoglycaemic coma | 31.72 | 12.74 | 20 | 26576 | 4341 | 70897507 |
Infusion related reaction | 30.67 | 12.74 | 18 | 26578 | 197516 | 70704332 |
Necrotising oesophagitis | 30.16 | 12.74 | 11 | 26585 | 702 | 70901146 |
Haemodynamic instability | 29.86 | 12.74 | 33 | 26563 | 15625 | 70886223 |
Tricuspid valve incompetence | 29.66 | 12.74 | 35 | 26561 | 17782 | 70884066 |
Haematocrit increased | 29.61 | 12.74 | 18 | 26578 | 3664 | 70898184 |
Left atrial enlargement | 29.23 | 12.74 | 12 | 26584 | 1054 | 70900794 |
Expired product administered | 29.11 | 12.74 | 22 | 26574 | 6391 | 70895457 |
Electrocardiogram Q wave abnormal | 28.74 | 12.74 | 10 | 26586 | 556 | 70901292 |
Aortic valve incompetence | 28.68 | 12.74 | 25 | 26571 | 8879 | 70892969 |
Hepatic function abnormal | 28.28 | 12.74 | 72 | 26524 | 67924 | 70833924 |
End stage renal disease | 27.59 | 12.74 | 27 | 26569 | 11106 | 70890742 |
Drug hypersensitivity | 27.31 | 12.74 | 35 | 26561 | 262424 | 70639424 |
Pericardial haemorrhage | 27.17 | 12.74 | 18 | 26578 | 4250 | 70897598 |
Lipase increased | 27.14 | 12.74 | 31 | 26565 | 15215 | 70886633 |
Hypohidrosis | 26.50 | 12.74 | 8 | 26588 | 282 | 70901566 |
Mitral valve incompetence | 25.40 | 12.74 | 40 | 26556 | 26688 | 70875160 |
Bundle branch block left | 25.36 | 12.74 | 25 | 26571 | 10374 | 70891474 |
Neoplasm | 25.27 | 12.74 | 22 | 26574 | 7802 | 70894046 |
Ventricular arrhythmia | 25.25 | 12.74 | 22 | 26574 | 7808 | 70894040 |
Echocardiogram abnormal | 24.97 | 12.74 | 13 | 26583 | 1966 | 70899882 |
Blood creatinine increased | 24.92 | 12.74 | 113 | 26483 | 142888 | 70758960 |
Arthralgia | 24.74 | 12.74 | 101 | 26495 | 503289 | 70398559 |
Headache | 24.62 | 12.74 | 123 | 26473 | 580282 | 70321566 |
Renal disorder | 24.56 | 12.74 | 48 | 26548 | 37961 | 70863887 |
Diabetic ketoacidotic hyperglycaemic coma | 23.92 | 12.74 | 7 | 26589 | 221 | 70901627 |
Amylase increased | 23.89 | 12.74 | 24 | 26572 | 10184 | 70891664 |
Left atrial dilatation | 23.09 | 12.74 | 14 | 26582 | 2835 | 70899013 |
Mucosal membrane hyperplasia | 23.05 | 12.74 | 5 | 26591 | 44 | 70901804 |
Mitral valve disease | 22.69 | 12.74 | 14 | 26582 | 2926 | 70898922 |
Syncope | 22.52 | 12.74 | 122 | 26474 | 165587 | 70736261 |
Carotid arteriosclerosis | 22.48 | 12.74 | 13 | 26583 | 2414 | 70899434 |
Occult blood | 22.31 | 12.74 | 11 | 26585 | 1483 | 70900365 |
Urine calcium/creatinine ratio increased | 22.16 | 12.74 | 6 | 26590 | 142 | 70901706 |
Erythema multiforme | 21.91 | 12.74 | 29 | 26567 | 16535 | 70885313 |
Sputum discoloured | 21.91 | 12.74 | 31 | 26565 | 18820 | 70883028 |
Blood phosphorus increased | 21.79 | 12.74 | 19 | 26577 | 6751 | 70895097 |
Diabetic foot | 21.62 | 12.74 | 14 | 26582 | 3180 | 70898668 |
Mucosal dryness | 21.54 | 12.74 | 14 | 26582 | 3202 | 70898646 |
Poikilocytosis | 21.37 | 12.74 | 7 | 26589 | 323 | 70901525 |
Acute myocardial infarction | 21.34 | 12.74 | 68 | 26528 | 72819 | 70829029 |
Systemic lupus erythematosus | 21.12 | 12.74 | 6 | 26590 | 101896 | 70799952 |
Acute lung injury | 20.73 | 12.74 | 13 | 26583 | 2796 | 70899052 |
Urethral caruncle | 20.67 | 12.74 | 5 | 26591 | 74 | 70901774 |
Marasmus | 20.63 | 12.74 | 9 | 26587 | 919 | 70900929 |
Hypoglycaemic encephalopathy | 20.44 | 12.74 | 8 | 26588 | 620 | 70901228 |
Red blood cell count decreased | 20.42 | 12.74 | 54 | 26542 | 52107 | 70849741 |
Depression | 20.21 | 12.74 | 27 | 26569 | 198947 | 70702901 |
Helicobacter gastritis | 20.12 | 12.74 | 12 | 26584 | 2359 | 70899489 |
Electrocardiogram T wave inversion | 20.10 | 12.74 | 16 | 26580 | 5015 | 70896833 |
Alopecia | 20.09 | 12.74 | 27 | 26569 | 198463 | 70703385 |
Peak expiratory flow rate decreased | 20.02 | 12.74 | 8 | 26588 | 655 | 70901193 |
Decreased appetite | 19.97 | 12.74 | 188 | 26408 | 304592 | 70597256 |
Dyspnoea at rest | 19.69 | 12.74 | 18 | 26578 | 6801 | 70895047 |
Hypovolaemia | 19.63 | 12.74 | 27 | 26569 | 15966 | 70885882 |
Supraventricular tachycardia | 19.43 | 12.74 | 30 | 26566 | 19680 | 70882168 |
Drug intolerance | 18.77 | 12.74 | 35 | 26561 | 225652 | 70676196 |
Bite | 18.75 | 12.74 | 7 | 26589 | 477 | 70901371 |
Blood uric acid increased | 18.73 | 12.74 | 20 | 26576 | 9109 | 70892739 |
Contraindicated product administered | 18.55 | 12.74 | 14 | 26582 | 134598 | 70767250 |
Pyelonephritis | 18.26 | 12.74 | 28 | 26568 | 18261 | 70883587 |
Neutropenia | 17.96 | 12.74 | 44 | 26552 | 257112 | 70644736 |
Rhinalgia | 17.71 | 12.74 | 9 | 26587 | 1295 | 70900553 |
Rhabdomyolysis | 17.68 | 12.74 | 77 | 26519 | 95683 | 70806165 |
Eosinophil count increased | 17.64 | 12.74 | 25 | 26571 | 15197 | 70886651 |
Insulin-like growth factor decreased | 17.53 | 12.74 | 7 | 26589 | 572 | 70901276 |
Gastric cancer | 17.29 | 12.74 | 19 | 26577 | 8936 | 70892912 |
Sinusitis | 17.14 | 12.74 | 23 | 26573 | 169172 | 70732676 |
Hypersensitivity | 17.10 | 12.74 | 38 | 26558 | 229774 | 70672074 |
Cardiomegaly | 17.09 | 12.74 | 32 | 26564 | 24513 | 70877335 |
Melaena | 16.89 | 12.74 | 53 | 26543 | 56302 | 70845546 |
Carotid artery stenosis | 16.82 | 12.74 | 18 | 26578 | 8218 | 70893630 |
Hypertensive heart disease | 16.82 | 12.74 | 13 | 26583 | 3903 | 70897945 |
Antibiotic level above therapeutic | 16.82 | 12.74 | 7 | 26589 | 636 | 70901212 |
Parathyroid hyperplasia | 16.79 | 12.74 | 5 | 26591 | 168 | 70901680 |
Wound | 16.78 | 12.74 | 8 | 26588 | 98724 | 70803124 |
Psoriasis | 16.69 | 12.74 | 8 | 26588 | 98425 | 70803423 |
Albuminuria | 16.65 | 12.74 | 7 | 26589 | 653 | 70901195 |
Bronchial hyperreactivity | 16.53 | 12.74 | 11 | 26585 | 2615 | 70899233 |
Arteriosclerosis coronary artery | 16.43 | 12.74 | 25 | 26571 | 16190 | 70885658 |
Pneumonia | 16.38 | 12.74 | 314 | 26282 | 595918 | 70305930 |
High density lipoprotein decreased | 16.24 | 12.74 | 13 | 26583 | 4106 | 70897742 |
Bronchitis viral | 16.24 | 12.74 | 8 | 26588 | 1077 | 70900771 |
Blood glucose decreased | 16.21 | 12.74 | 31 | 26565 | 24128 | 70877720 |
Discomfort | 15.81 | 12.74 | 10 | 26586 | 105426 | 70796422 |
Dust allergy | 15.58 | 12.74 | 8 | 26588 | 1176 | 70900672 |
Nephrogenic anaemia | 15.52 | 12.74 | 12 | 26584 | 3606 | 70898242 |
Haematocrit decreased | 15.49 | 12.74 | 52 | 26544 | 57206 | 70844642 |
Femoral neck fracture | 15.39 | 12.74 | 18 | 26578 | 9055 | 70892793 |
Urinary tract infection | 15.08 | 12.74 | 151 | 26445 | 248618 | 70653230 |
Oesophageal varices haemorrhage | 14.99 | 12.74 | 12 | 26584 | 3791 | 70898057 |
Latent autoimmune diabetes in adults | 14.92 | 12.74 | 4 | 26592 | 91 | 70901757 |
Epidermolysis | 14.91 | 12.74 | 6 | 26590 | 500 | 70901348 |
Glossodynia | 14.71 | 12.74 | 7 | 26589 | 86480 | 70815368 |
Drug eruption | 14.57 | 12.74 | 40 | 26556 | 39456 | 70862392 |
Incontinence | 14.52 | 12.74 | 21 | 26575 | 13007 | 70888841 |
Anxiety | 14.38 | 12.74 | 39 | 26557 | 220291 | 70681557 |
Hyperuricaemia | 14.20 | 12.74 | 19 | 26577 | 10947 | 70890901 |
Blood chloride increased | 14.16 | 12.74 | 13 | 26583 | 4940 | 70896908 |
Blood triglycerides increased | 14.15 | 12.74 | 26 | 26570 | 19638 | 70882210 |
Urine ketone body present | 14.04 | 12.74 | 11 | 26585 | 3368 | 70898480 |
Pruritus | 13.95 | 12.74 | 194 | 26402 | 345366 | 70556482 |
Serum ferritin increased | 13.86 | 12.74 | 17 | 26579 | 8988 | 70892860 |
Fatigue | 13.76 | 12.74 | 222 | 26374 | 824097 | 70077751 |
Adenosquamous cell lung cancer | 13.49 | 12.74 | 3 | 26593 | 30 | 70901818 |
Ureteric cancer recurrent | 13.40 | 12.74 | 3 | 26593 | 31 | 70901817 |
Blindness transient | 13.38 | 12.74 | 12 | 26584 | 4424 | 70897424 |
Hepatic encephalopathy | 13.17 | 12.74 | 27 | 26569 | 22091 | 70879757 |
Jaundice | 13.11 | 12.74 | 45 | 26551 | 50063 | 70851785 |
Hyperaesthesia teeth | 13.11 | 12.74 | 8 | 26588 | 1640 | 70900208 |
Intestinal obstruction | 13.03 | 12.74 | 38 | 26558 | 38787 | 70863061 |
Respiratory symptom | 12.96 | 12.74 | 11 | 26585 | 3770 | 70898078 |
None
Source | Code | Description |
---|---|---|
ATC | A10BD11 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD19 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD27 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BH05 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Dipeptidyl peptidase 4 (DPP-4) inhibitors |
MeSH PA | D054873 | Dipeptidyl-Peptidase IV Inhibitors |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D006728 | Hormones |
MeSH PA | D007004 | Hypoglycemic Agents |
MeSH PA | D054795 | Incretins |
MeSH PA | D011480 | Protease Inhibitors |
FDA MoA | N0000175912 | Dipeptidyl Peptidase 4 Inhibitors |
FDA EPC | N0000175913 | Dipeptidyl Peptidase 4 Inhibitor |
CHEBI has role | CHEBI:35526 | antidiabetic |
CHEBI has role | CHEBI:68612 | dipeptidyl peptidase-4 inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Diabetes mellitus type 2 | indication | 44054006 | DOID:9352 |
Pancreatitis | contraindication | 75694006 | DOID:4989 |
Hypoglycemic disorder | contraindication | 237630007 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.16 | Basic |
pKa2 | 6.13 | Basic |
pKa3 | 3.79 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
5MG | TRADJENTA | BOEHRINGER INGELHEIM | N201280 | May 2, 2011 | RX | TABLET | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR |
5MG | TRADJENTA | BOEHRINGER INGELHEIM | N201280 | May 2, 2011 | RX | TABLET | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH INSULIN (WITH OR WITHOUT METFORMIN AND/OR PIOGLITAZONE) |
5MG | TRADJENTA | BOEHRINGER INGELHEIM | N201280 | May 2, 2011 | RX | TABLET | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH PIOGLITAZONE |
5MG | TRADJENTA | BOEHRINGER INGELHEIM | N201280 | May 2, 2011 | RX | TABLET | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH SULFONLYUREA |
5MG | TRADJENTA | BOEHRINGER INGELHEIM | N201280 | May 2, 2011 | RX | TABLET | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA |
5MG | TRADJENTA | BOEHRINGER INGELHEIM | N201280 | May 2, 2011 | RX | TABLET | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH INSULIN (WITH OR WITHOUT METFORMIN AND/OR PIOGLITAZONE) |
2.5MG;1GM | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR |
2.5MG;1GM | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA |
2.5MG;500MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR |
2.5MG;500MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA |
2.5MG;850MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR |
2.5MG;850MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA |
10MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN |
10MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT INSULIN OR A SULFONYLUREA) |
10MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT METFORMIN) |
25MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN |
25MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT INSULIN OR A SULFONYLUREA) |
25MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT METFORMIN) |
2.5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR |
2.5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND, OPTIONALLY, A SULFONYLUREA |
5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR |
5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND, OPTIONALLY, A SULFONYLUREA |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN |
5MG | TRADJENTA | BOEHRINGER INGELHEIM | N201280 | May 2, 2011 | RX | TABLET | ORAL | 8673927 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
2.5MG;1GM | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8673927 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
2.5MG;500MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8673927 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
2.5MG;850MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8673927 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
10MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 8673927 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN |
10MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 9173859 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN |
25MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 8673927 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN |
25MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 9173859 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN |
2.5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8673927 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
2.5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 9173859 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8673927 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 9173859 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
2.5MG;1GM | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 10022379 | April 2, 2029 | USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS |
2.5MG;500MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 10022379 | April 2, 2029 | USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS |
2.5MG;850MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 10022379 | April 2, 2029 | USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS |
2.5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 10022379 | April 2, 2029 | USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS |
5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 10022379 | April 2, 2029 | USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10022379 | April 2, 2029 | METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10022379 | April 2, 2029 | METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10022379 | April 2, 2029 | METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10022379 | April 2, 2029 | METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID |
5MG | TRADJENTA | BOEHRINGER INGELHEIM | N201280 | May 2, 2011 | RX | TABLET | ORAL | 10034877 | Aug. 5, 2029 | TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN WITHOUT DOSE ADJUSTMENT |
5MG | TRADJENTA | BOEHRINGER INGELHEIM | N201280 | May 2, 2011 | RX | TABLET | ORAL | 9486526 | Aug. 5, 2029 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND WHO ARE INELIGIBLE FOR METFORMIN THERAPY BY ADMINISTERING LINAGLIPTIN |
10MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 8551957 | Oct. 14, 2029 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN |
25MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 8551957 | Oct. 14, 2029 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8551957 | Oct. 14, 2029 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8551957 | Oct. 14, 2029 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8551957 | Oct. 14, 2029 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8551957 | Oct. 14, 2029 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN |
5MG | TRADJENTA | BOEHRINGER INGELHEIM | N201280 | May 2, 2011 | RX | TABLET | ORAL | 8846695 | June 4, 2030 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
2.5MG;1GM | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8846695 | June 4, 2030 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
2.5MG;500MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8846695 | June 4, 2030 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
2.5MG;850MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8846695 | June 4, 2030 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10406172 | June 15, 2030 | METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10406172 | June 15, 2030 | METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10406172 | June 15, 2030 | METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10406172 | June 15, 2030 | METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN |
5MG | TRADJENTA | BOEHRINGER INGELHEIM | N201280 | May 2, 2011 | RX | TABLET | ORAL | 8853156 | March 5, 2031 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISINGMETFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISINGMETFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISINGMETFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISINGMETFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN |
2.5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 9555001 | March 6, 2033 | METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WHO HAVE NOT BEEN PREVIOUSLY TREATED WITH AN ANTIHYPERGLYCEMIC AGENT BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
2.5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 9555001 | March 6, 2033 | METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH ONE OR MORE CONVENTIONAL ANTIHYPERGLYCEMIC AGENTS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 9555001 | March 6, 2033 | METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WHO HAVE NOT BEEN PREVIOUSLY TREATED WITH AN ANTIHYPERGLYCEMIC AGENT BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 9555001 | March 6, 2033 | METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH ONE OR MORE CONVENTIONAL ANTIHYPERGLYCEMIC AGENTS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
10MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 10258637 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN |
10MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 11090323 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN |
25MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 10258637 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN |
25MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 11090323 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10258637 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 11090323 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2 |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10258637 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 11090323 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2 |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10258637 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 11090323 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2 |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10258637 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 11090323 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2 |
10MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 9949998 | June 11, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN |
25MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 9949998 | June 11, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 9949998 | June 11, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 9949998 | June 11, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 9949998 | June 11, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 9949998 | June 11, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
5MG | TRADJENTA | BOEHRINGER INGELHEIM | N201280 | May 2, 2011 | RX | TABLET | ORAL | July 3, 2022 | INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4 |
2.5MG;1GM | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | July 3, 2022 | INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4 |
2.5MG;500MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | July 3, 2022 | INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4 |
2.5MG;850MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | July 3, 2022 | INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4 |
10MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | July 3, 2022 | INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4 |
25MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | July 3, 2022 | INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4 |
2.5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | July 3, 2022 | INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4 |
5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | July 3, 2022 | INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4 |
5MG | TRADJENTA | BOEHRINGER INGELHEIM | N201280 | May 2, 2011 | RX | TABLET | ORAL | March 30, 2023 | ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME |
2.5MG;1GM | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | March 30, 2023 | ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME |
2.5MG;500MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | March 30, 2023 | ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME |
2.5MG;850MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | March 30, 2023 | ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME |
10MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | March 30, 2023 | ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME |
25MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | March 30, 2023 | ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME |
2.5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | March 30, 2023 | ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME |
5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | March 30, 2023 | ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Dipeptidyl peptidase 4 | Enzyme | INHIBITOR | IC50 | 10 | CHEMBL | CHEMBL | |||
Prolyl endopeptidase FAP | Enzyme | IC50 | 7.05 | CHEMBL | |||||
Dipeptidyl peptidase 9 | Enzyme | IC50 | 4 | CHEMBL | |||||
Muscarinic acetylcholine receptor M1 | GPCR | IC50 | 6.53 | CHEMBL | |||||
Prolyl endopeptidase FAP | Enzyme | IC50 | 6.43 | CHEMBL | |||||
Dipeptidyl peptidase IV | Unclassified | IC50 | 5 | CHEMBL |
ID | Source |
---|---|
4030725 | VUID |
N0000182735 | NUI |
D09566 | KEGG_DRUG |
4030725 | VANDF |
C2746078 | UMLSCUI |
CHEBI:68610 | CHEBI |
356 | PDB_CHEM_ID |
CHEMBL237500 | ChEMBL_ID |
D000069476 | MESH_DESCRIPTOR_UI |
DB08882 | DRUGBANK_ID |
6318 | IUPHAR_LIGAND_ID |
9039 | INN_ID |
3X29ZEJ4R2 | UNII |
10096344 | PUBCHEM_CID |
1100699 | RXNORM |
181237 | MMSL |
27861 | MMSL |
d07767 | MMSL |
013732 | NDDF |
702798009 | SNOMEDCT_US |
703667006 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Tradjenta | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0597-0140 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 33 sections |
Tradjenta | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0597-0140 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 33 sections |
Jentadueto | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0597-0146 | TABLET, FILM COATED | 2.50 mg | ORAL | NDA | 34 sections |
Jentadueto | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0597-0146 | TABLET, FILM COATED | 2.50 mg | ORAL | NDA | 34 sections |
Jentadueto | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0597-0147 | TABLET, FILM COATED | 2.50 mg | ORAL | NDA | 34 sections |
Jentadueto | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0597-0147 | TABLET, FILM COATED | 2.50 mg | ORAL | NDA | 34 sections |
Jentadueto | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0597-0148 | TABLET, FILM COATED | 2.50 mg | ORAL | NDA | 34 sections |
Jentadueto | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0597-0148 | TABLET, FILM COATED | 2.50 mg | ORAL | NDA | 34 sections |
Glyxambi | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0597-0164 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 32 sections |
Glyxambi | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0597-0164 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 32 sections |
Glyxambi | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0597-0164 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 32 sections |
Glyxambi | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0597-0182 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 32 sections |
Glyxambi | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0597-0182 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 32 sections |
Glyxambi | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0597-0182 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 32 sections |
Jentadueto XR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0597-0270 | TABLET, FILM COATED, EXTENDED RELEASE | 2.50 mg | ORAL | NDA | 34 sections |
Jentadueto XR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0597-0275 | TABLET, FILM COATED, EXTENDED RELEASE | 5 mg | ORAL | NDA | 34 sections |
Trijardy XR | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0597-0380 | TABLET, EXTENDED RELEASE | 5 mg | ORAL | NDA | 34 sections |
Trijardy XR | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0597-0380 | TABLET, EXTENDED RELEASE | 5 mg | ORAL | NDA | 34 sections |
Trijardy XR | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0597-0385 | TABLET, EXTENDED RELEASE | 2.50 mg | ORAL | NDA | 34 sections |
Trijardy XR | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0597-0385 | TABLET, EXTENDED RELEASE | 2.50 mg | ORAL | NDA | 34 sections |
Trijardy XR | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0597-0390 | TABLET, EXTENDED RELEASE | 5 mg | ORAL | NDA | 34 sections |
Trijardy XR | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0597-0390 | TABLET, EXTENDED RELEASE | 5 mg | ORAL | NDA | 34 sections |
Trijardy XR | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0597-0395 | TABLET, EXTENDED RELEASE | 2.50 mg | ORAL | NDA | 34 sections |
Trijardy XR | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0597-0395 | TABLET, EXTENDED RELEASE | 2.50 mg | ORAL | NDA | 34 sections |
Tradjenta | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-4383 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 29 sections |
Jentadueto | HUMAN PRESCRIPTION DRUG LABEL | 2 | 54868-6461 | TABLET, FILM COATED | 2.50 mg | ORAL | NDA | 28 sections |
Tradjenta | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55154-0410 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 31 sections |
Tradjenta | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55154-0410 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 31 sections |
Tradjenta | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55154-0410 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 31 sections |
Jentadueto | HUMAN PRESCRIPTION DRUG LABEL | 2 | 63629-6524 | TABLET, FILM COATED | 2.50 mg | ORAL | NDA | 31 sections |